Clinical trials: Early Rheumatoid Arthritis
Rheumatoid Arthritis
Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis
This non-interventional, descriptive, cross-sectional and multicenter study will examine the treatment of rheumatoid arthritis progressing for less than two years in the Algerian population.
- Trial name
- NCT02008266
- Volunteers
- 532 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06970951
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Rheumatoid Arthritis
Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission…
- Trial name
- NCT01142726
- Testing
- Abatacept, Methotrexate
- Where
- 73 sites in United States, Australia and 13 more
- Volunteers
- 511 people
- Sponsor
- Bristol-Myers Squibb
Arthritis Rheumatoid
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.
- Trial name
- NCT04721821
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 7,807 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate…
- Trial name
- EXPAND (NCT05516979)
- Testing
- 100 mg AP1189
- Where
- Moldova
- Volunteers
- 127 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with repeated doses of AP1189. The study population will consist of newly diagnosed subjects with severe active Rheumatoid Arthritis…
- Trial name
- BEGIN (NCT04004429)
- Testing
- 50 mg AP1189, AP1189
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 105 people
- Sponsor
- SynAct Pharma Aps
Rheumatoid Arthritis
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in…
- Trial name
- MARVELOUS (NCT01235598)
- Testing
- Certolizumab Pegol (CZP) 200 mg, Certolizumab Pegol (CZP) 400 mg
- Where
- 10 sites in Denmark, Netherlands and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease.
- Trial name
- NCT02647762
- Testing
- CF101 1 mg, CF101 2 mg, MTX
- Where
- 35 sites in Bosnia and Herzegovina, Canada and 5 more
- Volunteers
- 244 people
- Sponsor
- Can-Fite BioPharma
Rheumatoid Arthritis
Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve.
- Trial name
- NCT01164579
- Testing
- Tasocitinib plus Methotrexate
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with…
- Trial name
- NCT01034137
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 21 sites in Netherlands
- Volunteers
- 317 people
- Sponsor
- Hoffmann-La Roche
Early Rheumatoid Arthritis
Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis
This is a phase Ib study to investigate the safety, pharmacokinetics and preliminary efficacy of ginsenoside compound K (GCK) tablets in patients with rheumatoid arthritis. This study is to be run in China involving 10-12 sites.
- Trial name
- NCT03755258
- Testing
- GCK 300 mg
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Rheumatoid Arthritis, DMARD-naive and Early Disease Patients
A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
CR6086 is a new, potent and selective, orally available, small molecule prostaglandin EP4 receptor antagonist, endowed with immunomodulatory properties.
- Trial name
- NCT03163966
- Testing
- CR6086, Methotrexate
- Where
- Czechia
- Volunteers
- 248 people
- Sponsor
- Rottapharm Biotech
Rheumatoid Arthritis
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced…
- Trial name
- RADAR (NCT01162421)
- Testing
- adalimumab, Methotrexate
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA
A key challenge in the management of patients with Rheumatoid Arthritis (RA) is the early identification of patients that are at risk of developing a severe and destructive disease.
- Trial name
- NCT01078597
- Where
- 4 sites in Ireland
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)
This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week…
- Trial name
- NCT01668966
- Testing
- Tocilizumab
- Where
- 6 sites in Brazil
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
The objective of this study is to assess the efficacy of certolizumab pegol (CZP) with methotrexate (MTX) compared with MTX-alone in patients with early-stage rheumatoid arthritis (RA) who are naive to MTX and have with poor…
- Trial name
- NCT01451203
- Testing
- CZP, methotrexate (MTX)
- Where
- 8 sites in Japan
- Volunteers
- 319 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Comorbidities and Outcomes in Early Rheumatoid Arthritis
Identify the burden of comorbidity at the time of diagnosis of rheumatoid arthritis. Identify the impact of comorbidity present at diagnosis on cardiovascular disease, death, rheumatoid arthritis disease progression and…
- Trial name
- NCT03675516
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 13,182 people
- Sponsor
- Momentum Data
Early Rheumatoid Arthritis
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)
The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
- Trial name
- CONCERTO (NCT01185301)
- Testing
- adalimumab, methotrexate
- Where
- 68 sites in United States, Argentina and 8 more
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis,Rheumatoid
Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
To determine if early clinical response at 12 weeks to Certolizumab Pegol (CZP, Cimzia ®) therapy in adult Rheumatoid Arthritis (RA) patients is a predictor of better long term clinical response at 18 months compared with a lack…
- Trial name
- RA-PROACTIVE (NCT01288287)
- Where
- 22 sites in Ireland, United Kingdom
- Volunteers
- 149 people
- Sponsor
- UCB Pharma
Still's Disease, Adult-Onset
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
The objective of this study is to assess safety, tolerability and early signs of efficacy of the investigational drug Tadekinig alfa in Adult-onset Still's disease, a rare polygenic auto-inflammatory disorder for which treatment…
- Trial name
- NCT02398435
- Testing
- Tadekinig alfa (recombinant human IL-18 binding protein)
- Where
- 20 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- AB2 Bio Ltd.